Cargando…

Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT

Detalles Bibliográficos
Autores principales:	Koenecke, Christian, Eikema, Dirk-Jan, Hazelaar, Sheree, Schroeder, Thomas, Potter, Victoria, Kröger, Nicolaus, Bornhäuser, Martin, Finke, Jürgen, Platzbecker, Uwe, Radujkovic, Aleksandar, Ganser, Arnold, Salmenniem, Urpu, Blaise, Didier, Kobbe, Guido, Meijer, Ellen, Friis, Lone, Maertens, Johan, Caballero, Dolores, Cornelissen, Jan J., Olivieri, Attilio, Gulsum, Ozet, Hayden, Patrick J., Onida, Francesco, Robin, Marie, Yakoub-Agha, Ibrahim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532241/ https://www.ncbi.nlm.nih.gov/pubmed/35871086 http://dx.doi.org/10.1038/s41409-022-01759-7

Ejemplares similares

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
por: Valent, Peter, et al.
Publicado: (2019)

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
por: Gagelmann, Nico, et al.
Publicado: (2019)

Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT
por: Robin, Marie, et al.
Publicado: (2023)

Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT
por: Poiré, Xavier, et al.
Publicado: (2020)

Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT
por: Penack, Olaf, et al.
Publicado: (2021)

Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study
por: Ruutu, Tapani, et al.
Publicado: (2023)

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
por: Hayden, Patrick J., et al.
Publicado: (2021)

Mouse Models of CMML
por: Belotserkovskaya, Ekaterina, et al.
Publicado: (2021)

Combined Channel Estimation with Interference Suppression in CPSS
por: Lai, Xiaoyang, et al.
Publicado: (2018)

Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT
por: Devillier, Raynier, et al.
Publicado: (2023)

Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
por: Raj, Kavita, et al.
Publicado: (2022)

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
por: Chihara, Dai, et al.
Publicado: (2022)

Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum
por: Calvo, Xavier, et al.
Publicado: (2022)

Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study
por: Greinix, Hildegard T., et al.
Publicado: (2021)

The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT
por: Tournilhac, Olivier, et al.
Publicado: (2023)

CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
por: Bezerra, Evandro D., et al.
Publicado: (2021)

Hepatic encephalomyelopathy in a calf with congenital portosystemic shunt (CPSS)
por: Marçal, Valéria Café, et al.
Publicado: (2008)

Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study
por: Ruggeri, Annalisa, et al.
Publicado: (2016)

Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
por: Penack, Olaf, et al.
Publicado: (2023)

An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA
por: Rejeski, Kai, et al.
Publicado: (2023)

Testing the clinical application of the child psychosis-risk screening system (CPSS)
por: Hamasaki, Y., et al.
Publicado: (2021)

Toward the clinical application of the Child Psychosis-Risk Screening System (CPSS)
por: Hamasaki, Y., et al.
Publicado: (2022)

S260: IMMUNE EFFECTOR CELL ASSOCIATED HEMATOTOXICITY (ICAHT) FOLLOWING CAR T-CELL THERAPY: INTERNATIONAL SURVEY AND CONSENSUS GUIDELINES ON ITS GRADING, DIAGNOSIS, AND MANAGEMENT ON BEHALF OF EHA AND EBMT
por: Rejeski, Kai, et al.
Publicado: (2023)

Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT
por: Brissot, Eolia, et al.
Publicado: (2019)

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus
por: Passweg, Jakob R., et al.
Publicado: (2020)

Smooth Sensor Motion Planning for Robotic Cyber Physical Social Sensing (CPSS)
por: Tang, Hong, et al.
Publicado: (2017)

Editorial: Population genomic architecture: Conserved polymorphic sequences (CPSs), not linkage disequilibrium
por: Alper, Chester A., et al.
Publicado: (2023)

Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML).
por: Stark, A. N., et al.
Publicado: (1987)

Transformation of CMML to AML presenting with acute kidney injury
por: DeBoer, Rebecca, et al.
Publicado: (2020)

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
por: Yakoub-Agha, Ibrahim, et al.
Publicado: (2020)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia
por: Schetelig, Johannes, et al.
Publicado: (2018)

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
por: Tilmont, Rémi, et al.
Publicado: (2023)

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML
por: Laborde, R R, et al.
Publicado: (2013)

Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
por: Penack, Olaf, et al.
Publicado: (2023)

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
por: Passweg, Jakob R., et al.
Publicado: (2019)

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies
por: Padron, E, et al.
Publicado: (2015)

CPSS 2.0: a computational platform update for the analysis of small RNA sequencing data
por: Wan, Changlin, et al.
Publicado: (2017)

Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years
por: Passweg, Jakob R., et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT
por: Chalandon, Yves, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nispqgkrl8vn90pqmljurdm6vs